@WolfofWeedST Tuesday, 08/29/17 01:04:38 PM Re: None Post # of 309 Sure... I added this am https://twitter.com/wolfofweedst/status/902525929599234048 The cliff notes version is that they are spending a lot of money in the build out of their facilities as expected because of impending recreational market. They are also sitting on a lot of oil they can sell and are waiting on the approval to sell from health Canada. That will be a catalyst for sure. Another thing to point out is that a lot of the cannabis they grew was not reflected in these earnings and will be reflected next quarter. Cash wise they have $24m in reserve and Echelon Partners has a price target of $2.50 CAD ($2usd) for them which they downgraded from $4.5cad because of lower expected #'s. What's not being factored in in my opinion is the Biotech division led by John Stewart formerly ceo of Purdue Pharma (makers of OxyContin). For me, I'm banking on Biotech and Stewart. He brought 11 other drugs to market and if he can do that here it would be a windfall for longs. The fact they grow weed is just a bonus, but $2 pps target would make this a 48% gainer. And as a long I'm looking at a 2018 trade horizon depending on strength, but with Biotech $5-$10 would not shock me. And compared to Canopy and aurora which have market caps between 800m to 1.3b I believe makes emblem 1 of the most undervalued LP's in Canada. I've increased my position from 89,500 to 100,500 in last week. But I suggest you do some more research on Stewart. Here's a good start- http://www.bbc.com/news/amp/world-us-canada-38083737 Happy trading and good luck.